| abstract |
Muscarinic receptor antagonists, characterized in that they comprise a multiaglutinating compound comprising from 2 to 10 ligands covalently attached to one or more bonds, where each of said ligands independently comprises, a muscarinic receptor antagonist or an allosteric modulator of a muscarinic receptor and its salts of pharmaceutical acceptance, with the proviso that at least one of said ligands is a muscarinic receptor antagonist, and with the condition that when the multi-binding compound comprises 2 or three ligands, then only one of the ligands is 11-acetyl-5 , 11-dihydro-6H-pyrido [2,3] [1,4] -benzodiazepin-6-one, N-methylquiniclidine, or a compound of the group of formulas (I) in which n (a) is 0 or 1; R (c) is hydrogen or alkyl; R (d) is hydrogen and R (e) is -CO2CRf (phenyl) 2, where R (f) is hydrogen or hydroxy, useful in the treatment and prevention of diseases such as chronic obstructive pulmonary disease, chronic bronchitis, irritable bowel syndrome , urinary incontinence and similar. In addition, pharmaceutical composition, use of said antagonists for the manufacture of a medicament, a method for identifying multimeric ligand compounds having multiagglutinating properties, a library of multimeric ligand compounds and an iterative method for identifying multimeric ligand compounds are described. |